The oligosaccharides α-Kdop-(2→8)-α-Kdop-(2→6)-β-D-GlcpNAc-(1→OAll) 4, α-Kdop-(2→4)-α-
INTRODUCTION
Chlamydiae are bacteria of small dimensions (200-300 nm in size) occurring as strictly intracellular parasites in human and animal cells. According to a recent taxonomic reclassification, they have been placed in one order (Chlamydiales) comprising three families (Chlamydiaceae, Simkaniaceae, and Parachlamydiaceae). 1 Within Chlamydiaceae, two genera -Chlamydia and Chlamydophila -have been proposed, with nine different species identified thus far. 2 Chlamydiae are responsible for various acute or chronic diseases in animals and humans. 3 Whereas infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae strains are of increasing biomedical importance, Chlamydophila psittaci plays a role as a pathogen mainly in veterinary medicine. 4 The species has been detected in sheep, cattle, cats, and most frequently in birds, which may transmit the organism to humans leading to severe atypical pneumonia known as ornithosis or psittacosis.
The cell wall of chlamydiae harbors a group-specific glycolipid epitope which was shown to be composed of a linear Kdo trisaccharide of the sequence α-Kdo-(2→8)α-Kdo-(2→4)-α-Kdo, 5, 6 whereas Chl. psittaci LPS contains on average 4.6 residues of Kdo per mol of LPS. 7 The gene coding for the Kdo transferase of Chl. psittaci 6BC has been cloned, expressed in the deep rough mutant Escherichia coli F515 and sequenced. 8 Interestingly, the deduced amino acid sequence of the Chl. psittaci Kdo transferase (~46 kDa) shares only 67% overall homology compared to that of Chl. trachomatis, but the enzyme is also capable of generating the group-specific structure as determined by SDS-PAGE and Western blot analysis using a Chlamydia-specific LPS-antibody. 9 In addition to the group-specific α-Kdo-(2→8)-α-Kdo-(2→4)-α-Kdo trisaccharide determinant, other oligosaccharides such as the pentasaccharide α-Kdo-(2→4)-α-Kdo-(2→4)-α-Kdo-(2→6)-β-D-GlcN-(1→6)-D-GlcN and the branched hexasaccharide α-Kdo-(2→4)-[α-Kdo-(2→8)]-α-Kdo-(2→4)α-Kdo-(2→6)-β-D-GlcN-(1→6)-D-GlcN were isolated from degraded LPS of a recombinant strain expressing the multifunctional Chl. psittaci Kdo transferase. 10 We are interested in understanding the specificity of antibodies against the chlamydial Kdo region since the antibodies are useful to identify chlamydiae at the genus level and since they are regarded as a model to study protein-carbohydrate interactions which are of broad biological impact. The epitopes recognized by these antibodies used in this study are schematically displayed in Figure 1 .
The presence of the unique branched Kdo-tetrasaccharide in the LPS of Chl. psittaci should enable the generation and characterization of species-specific monoclonal antibodies, which should not cross-react with the group specific Kdo trisaccharide epitope. Such antibodies would be useful to identify Chl. psittaci and to differentiate them from Chl. trachomatis and Chl. pneumoniae strains. Here, we report on the chemical synthesis of neoglycoproteins containing the Kdo tetrasaccharide as well as part structures thereof, which were used in serological studies.
MATERIALS AND METHODS

General methods
Melting points were determined with a Kofler hot stage and are uncorrected. Optical rotations were measured with a Perkin-Elmer 243 B Polarimeter.
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-values are given in units of 10 -1 deg.cm 2 g -1 . 1 H-NMR spectra were recorded at 297 K with a Bruker DPX instrument operating at 300 MHz for 1 H using CDCl 3 as solvent and tetramethylsilane as standard, unless stated otherwise. 13 C-NMR spectra were measured at 75.47 MHz and referenced to 1,4 dioxane (δ 67.40). Homo-and heteronuclear 2D NMR spectroscopy was performed with Bruker standard software. Thin layer chromatography was performed on Merck precoated plates (5 x 10 cm, layer thickness 0.25 mm, Silica Gel 60F 254 ); spots were detected by spraying with anisaldehyde-H 2 SO 4 . For column chromatography, silica gel (0.040-0.063 mm, 10 µm for HPLC) was used. Concentration of solutions was performed at reduced pressure at temperatures < 40°C. Elemental analyses were provided by Dr J. Theiner, Mikroanalytisches Laboratorium, Institut für Physikalische Chemie, Universität Wien, Austria.
Allyl [methyl (4,5,7,8- 
To a suspension of 2 (200 mg, 0.4 mmol), Hg(CN) 2 (30 mg, 0.12 mmol), HgBr 2 (20 mg, 0.056 mmol) and mole- Fig. 1 . Schematic representation of epitope specificities of mAb binding to the carbohydrate backbone of chlamydial LPS. Antibodies of type A (mAb A20) and B (mAb S25-38) recognize an α-pyranosidically linked Kdo residue or the α-(2→4)-linked Kdo disaccharide, structures occuring in chlamydial and other LPS. Antibodies of type C (mAb S25-2) and D (mAb S25-23) recognize the disaccharide α-Kdo-(2→8)-α-Kdo and the trisaccharide α-Kdo-(2→8)-α-Kdo-(2→4)-α-Kdo, respectively. The 2→8 linkage, present in the latter two structures, has not been detected in other bacteria or natural products, and thus, is a chemotaxonomic marker for Chlamydia. cular sieves 4Å (1 g) in MeNO 2 (2 ml) was added a solution of 1 (90 mg, 0.11 mmol) in dry MeNO 2 (3 ml) at room temperature. The suspension was stirred for 40 h, diluted with CH 2 Cl 2 (30 ml) and filtered. The filtrate was washed with 5% aqueous KI, saturated aqueous NaHCO 3 , dried (MgSO 4 ) and concentrated. Purification of the residue on silica gel (1:2, hexane-EtOAc) afforded a mixture of anomers which was separated by HPLC (Si 60, 10 µm) to give pure 3 (20 mg 
A solution of 3 (15.3 mg, 0.012 mmol) in THF (2 ml) was stirred at 0°C with 1.1 M tetrabutylammonium fluoride in THF (0.1 ml) for 30 min. MeOH (2 ml) was added and the solution was concentrated. Additional methanol (5 ml) was added and the solution was stirred with 0.1 M methanolic sodium methoxide (0.5 ml) for 3 h at room temperature. The solution was made neutral by addition of Dowex resin (H + form), filtered and taken to dryness. The residue was dissolved in water (2 ml) and treated with 0.2 M NaOH (0.5 ml) for 30 min. Dowex resin (H + form) was then added until the solution reached pH 8; the solution was concentrated and purified on Bio-Gel P2 (95:5 water-EtOH) to give 4 as amorphous solid. Yield: 9 mg, (~100%); [α] D 20 +30.5 (c 0.9, water). 1 
A solution of 4 (5.0 mg, 7 µmol) and cysteamine hydrochloride (11.4 mg, 0.1 mmol) in water (1 ml) was irradiated at 254 nm for 3 days at room temperature. The solution was passed through a column of Dowex AG 1X8 resin (NH 4 + form) using 0. 
BSA-conjugate 6
A solution of 5 (3.0 mg, 3.5 µmol) in 0.1 M NaHCO 3 (1 ml) was vigorously stirred with a solution of thiophosgene (26 µmol) in CHCl 3 (2 ml) for 1 h at room temperature. The organic layer was removed and the aqueous phase was washed twice with CHCl 3 (3 ml) and purged with N 2 . A solution of bovine serum albumin (3.7 mg) in 0.1 M NaHCO 3 /0.3 M NaCl was added and stirring was continued for 60 h. The solution was passed through a column of Sephadex G-25 using 0.01 M NaHCO 3 as eluent. Ninhydrine-positive fractions were combined, dialyzed against water and lyophilized to give 6 as a white powder. Yield: 3.6 mg.
A suspension of 8 (122 mg, 0.16 mmol), Hg(CN) 2 (34 mg, 0.135 mmol), HgBr 2 (15 mg, 0.042 mmol) and molecular sieves 4Å (1 g) in dry MeCN (3 ml) was stirred for 20 min at room temperature. A solution of 7 (73 mg, 0.086 mmol) in MeCN (1 ml) was added and the solution was stirred for 2 days. EtOAc (50 ml) was added, the suspension was filtered, and the filtrate was washed with 5% aq KI, then saturated aqueous NaHCO 3 , dried (Na 2 SO 4 ) and concentrated. Purification of the residue on silica gel (EtOAc-toluene 2:16 5:1) afforded 9 as a colorless syrup. Yield: 19 mg (15%). 
A solution of 9 (5.7 mg, 3.7 µmol) in THF (2 ml) was stirred at 0°C with 1.1 M tetrabutylammonium fluoride in THF (0.02 ml) for 60 min. MeOH (1 ml) was added and the solution was concentrated. Methanol (5 ml) was added and the solution was stirred with 0.1 M methanolic sodium methoxide (0.5 ml) for 2 h at room temperature. The solution was made neutral by addition of Dowex resin (H + form), filtered and taken to dryness The residue was dissolved in water (2 ml) and treated with 0.2 M NaOH (1 ml) for 15 h. Dowex resin was then added until the solution reached pH 10; the solution was concentrated and purified on Sephadex G-10 (95:5 water-EtOH) to give 10 as an amorphous solid. Yield: 3.6 mg, (99%); [α] D 20 +44 (c 0.3, water). 1 (3- (11) A solution of 10 (3.5 mg, 3.5 µmol) and cysteamine hydrochloride (11.4 mg, 0.1 mmol) in water (1 ml 
3-(2-Aminoethylthio)propyl [ammonium
deoxy-α-D- manno-oct-2-ulopyranosyl) onate]-(2→4)-[ammonium (3-deoxy-α-D-manno-oct-2-ulopyranosyl)onate]- (2→4)-[ammonium (3-deoxy-α-D-manno-oct-2- ulopyranosyl)onate]-(2→6)-2-acetamido-2-deoxy-β-D- glucopyranoside hydrochloride
BSA-conjugate 12
A solution of 11 (3.0 mg, 2.9 µmol) in 0.1 M NaHCO 3 (1 ml) was vigorously stirred with a solution of thiophosgene (13 µmol) in CHCl 3 (1 ml) for 3 h at room temperature. The organic layer was removed and the aqueous phase was washed twice with CHCl 3 (3 ml) and purged with N 2 . A solution of bovine serum albumin (4.1 mg) in 0.1 M NaHCO 3 /0.3 M NaCl was added and processed as described for 6 to give 12 as a white powder. Yield: 4.5 mg.
Benzyl [methyl (4,5,7,8- 
A suspension of 13 (169 mg, 0.214 mmol), Hg(CN) 2 (126 mg, 0.5 mmol) and molecular sieves 4Å (1 g) in dry MeNO 2 (3 ml) was stirred for 30 min at room temperature. A solution of 14 (205 mg, 0.43 mmol) in MeNO 2 (2 ml) was added and the suspension was stirred for 20 h at room temperature. EtOAc (50 ml) was added, the suspension was filtered, and the filtrate was washed with 5% aq KI, then saturated aqueous NaHCO 3 [Methyl (4,5,7,8- 
A solution of 15 (81.7 mg) in dry MeOH (4 ml) was treated with hydrogen and 10% Pd-C (30 mg) for 1.5 h at room temperature. The suspension was filtered over a pad of Celite and the filtrate was evaporated to dryness. The residue (68 mg) was dissolved in dry pyridine (5 ml), 4-N,N-dimethylamino pyridine (20 mg) and acetic anhydride (1 ml) were added at 0°C . The solution was stirred overnight at room temperature. MeOH (0.5 ml) was added and the solution was concentrated by repeated coevaporation with toluene. The residue was purified on a column of silica gel (toluene-EtOAc 1:2) affording 16 [Methyl (4,5,7,8- (19) and allyl [methyl (4,5,7,8- (20) A solution of 16 (61.8 mg) in dry dichloromethane (20 ml) was stirred with TiBr 4 (160 mg) for 24 h at 4°C. The solution was diluted with cold CHCl 3 , washed with cold saturated aqueous NaHCO 3 , dried (MgSO 4 ) and taken to dryness to afford the bromide 17 (63.1 mg) as a slightly yellow syrup. A suspension of 18 (60 mg, 0.2 mmol), Hg(CN) 2 (16 mg, 0.06 mmol), HgBr 2 (11 mg, 0.03 mmol) and molecular sieves 4Å (1 g) in dry MeNO 2 (3 ml) was stirred for 30 min at room temperature. A solution of the bromide 17 in dry MeNO 2 (1 ml) was added under N 2 and stirring was continued for 2 days. Work-up as described for 9 and purification of the residue on silica gel (EtOAc-toluene 2:1) afforded first 19 as a colorless syrup. Yield: 38.6 mg (66%). 
tetra-O-acetyl-3-deoxy-α-D-mannooct-2-ulopyranosyl)onate]-(2→4)-{methyl (4,5,7,8tetra-O-acetyl-3-deoxy-α-D-manno-oct-2-ulopyranosyl) onate-(2→8)}-[methyl (5,7-di-O-acetyl-2,6-anhydro-2,3-dideoxy-D-manno-oct-2-enopyranos)onate]
A solution of 20 (7.6 mg, 5.2 µmol) in dry MeOH (2 ml) was stirred with 0.1 M methanolic sodium methoxide (1.0 ml) for 2 h at room temperature. The solution was made neutral by addition of Dowex resin (H + form), filtered and taken to dryness.The residue was dissolved in water (2 ml) and treated with 1.5 M NaOH (0.2 ml) for 2 h. Dowex resin was then added until the solution was pH 7.5. The solution was concentrated and purified on Bio-Gel P2 (95:5 water-EtOH) to give 21 as an amorphous solid. Yield: 5.3 mg (~100% 
3-(2-Aminoethylthio)propyl [ammonium (3-deoxy-α-Dmanno-oct-2-ulopyranosyl)onate]-(2→4)-{ammonium (3-deoxy-α-D-manno-oct-2-ulopyranosyl)onate]-(2→8)}-[ammonium (3-deoxy-α-D-manno-oct-2ulopyranosyl)onate]-(2→4)-[ammonium (3-deoxy-α-D-manno-oct-2-ulopyranosid)onate] (22)
A solution of 21 (3.45 
BSA-conjugate 23
A solution of 22 (2.3 mg, 2.4 µmol) in 0.1 M NaHCO 3 (1 ml) was vigorously stirred with a solution of thiophosgene (13 µmol) in CHCl 3 (1 ml) for 6 h at room temperature. The organic layer was removed and the aqueous phase was washed twice with CHCl 3 (3 ml) and purged with N 2 . A solution of bovine serum albumin (2.9 mg) in 0.1 M NaHCO 3 /0.3 M NaCl was added and processed as described for 6 to give 23 as a white powder. Yield: 2.3 mg.
Monoclonal antibodies (mAb) and serology
Monoclonal antibodies A20, S25-2, and S25-23 have been described. 11, 12 Mab S25-38 has been isolated for this study from the same fusion; 12 it is an IgG 1 isotype and was selected on the basis of similar binding to the 2→4-and 2→8-linked Kdo disaccharide. All antibodies were used as purified immunoglobulins obtained after affinity chromatography as described. 13 Binding of mAb to neoglycoconjugates was determined by enzyme immuno-assay (EIA) as described in detail elsewhere. 13 Briefly, varying amounts of neoglycoconjugates antigens were coated onto 96-well microtiter plates and tested against serial dilutions of antibody. Experiments were set up in quadruplicates and mean values were calculated. Confidence values did not exceed 10%.
RESULTS AND DISCUSSION
For the synthesis of the trisaccharide 4, which corresponds to an artificial structure and has not been found in chlamydiae, the previously described disaccharide bromide donor 1 14 was coupled to the protected glucosamine acceptor 2 15 in the presence of Hg(CN) 2 /HgBr 2 (Fig. 2) . Using MeCN as solvent, a mixture of trisaccharides was isolated in 28% yield in 1:3 α/β ratio, whereas the α-configured product 3 was obtained as the major isomer (5:1 α/β ratio) by performing the reaction in MeNO 2 . The mixture was separated by HPLC on silica gel to afford pure 3 in 15% yield. The α-anomeric configuration of the proximal, (2→6)-linked Kdo unit was evident from the absence of a low-field shifted signal of the equatorial H-3′ and presence of the low-field shift of H-4′ (δ 5.13). Deblocking of the protected trisaccharide derivative 3 was accomplished by removal of the silyl ether groups with Bu 4 NF in THF, subsequent sodium methoxide treatment followed by hydrolysis of the methyl ester groups in 0.2 M NaOH furnished the trisaccharide allyl glycoside 4 in quantitative yield. Addition of cysteamine to the allyl group 16, 17 gave the spacer-derivative 5, which was isolated after ion-exchange chromatography in 55% yield. The 3-(2-aminoethylthio)propyl glycoside 5 was then reacted with thiophosgene 18 to afford the isothiocyano derivative which was subsequently coupled with bovine serum albumin to afford the neoglycoprotein 6.
For the synthesis of neoglycoproteins containing Kdostructures occurring in the inner core of Chl. psittaci LPS, the tetrasaccharide α-Kdo-(2→4)-α-Kdo-(2→4)-α-Kdo-(2→6)-β-D-GlcNAc-(1→OAllyl) 10 was chosen in order to study the influence of the adjoining glucosamine unit for the antibody specificities. Coupling of the previously described 7′,8′-O-carbonyl protected α-Kdo-(2→6)-β-D-GlcNAc disaccharide acceptor 8 19 with the known Kdo disaccharide bromide derivative 7 20, 21 gave only low yields of the α-(2′′→4′)-linked tetrasaccharide compound 9 (Fig.  3) . Whereas similar glycosylation reactions with a Kdo monosaccharide acceptor and the disaccharide bromide 7 afforded products in ~50% yields [19] [20] [21] , the yield of tetrasaccharide could not be improved by using different solvent and catalyst systems. By using MeNO 2 -Hg(CN) 2 /HgBr 2 , the tetrasaccharide 9 was isolated in only 10% yield, the major by-product formed was the Kdo-disaccharide glycal ester, originating from the bromide 7 upon HBr-elimination. Slightly better yields were obtained in MeCN as solvent and Hg(CN) 2 /HgBr 2 as promotor which furnished the tetrasaccharide derivative 9 in 15% yield. The compound was isolated by silica gel chromatography and deprotected in nearly quantitative yield as described for 4, which gave the tetrasaccharide allyl glycoside 10. The allyl glycoside Synthesis of neoglycoproteins containing Kdo epitopes specific for Chlamydophila psittaci LPS 63 was then converted into the spacer derivative 11 and linked to BSA to afford the neoglycoprotein 12.
For the synthesis of the branched Kdo-tetrasaccharide 21, the previously described Kdo-disaccharide acceptor 13 20 was coupled with the Kdo bromide donor 14 in a regioselective reaction to give the α-(2′′→8)-linked trisaccharide 15 as the major glycosylation product in 59% yield (Fig. 4) . The structural assignments were confirmed The major reaction product formed was the trisaccharide glycal ester 19, which was isolated in 66% yield by column chromatography on silica gel. The compound, however, may be recycled into the precursor 16 using acetoxyiodination followed by reduction. 22 The tetrasaccharide derivative 20 was obtained in 32% yield, but was contaminated with a small amount (3%) of the β-(2′→4)-linked isomer, which was removed by preparative HPLC. Deprotection of the Finally, addition of cysteamine hydrochloride furnished the spacer derivative 22 in 93% yield, which was subsequently coupled to BSA to give the neoglycoconjugate 23. The ligand/protein ratio was determined using a protein assay as well as a quantitative determination of the Kdo units using the thiobarbituric acid assay. 23 The ligand to protein ratio was 227 nmol/mg BSA for 6, 106 nmol/mg BSA for 12 and 97 nmol/mg BSA for 23. The neoglycoconju-Synthesis of neoglycoproteins containing Kdo epitopes specific for Chlamydophila psittaci LPS 67 Fig. 5 . Binding of monoclonal antibodies (mAb) to synthetic neoglycoconjugates. The synthetic neoglycoconjugates α-Kdo-(2→8)-α-Kdo-(2→4)-α-Kdo-BSA (column 1) and 6, 12 and 23 (columns 2, 3 and 4, respectively) were coated to microtiter plates in amounts of 10 (circles), 2.5 (triangles), 0.63 (squares) and 0.16 (diamonds) pmol/well and reacted with the antibody concentrations indicated in the abscissa, followed by reaction with enzyme-labeled second antibody and substrate. OD values were determined photometrically at 405 nm in quadruplicate. Confidence values did not exceed 10%. The antibodies used were the Kdo monosaccharide-specific antibody A20 (A), the 2→4-and 2→8-disaccharide-specific antibody S25-38 (B), the 2→8 disaccharide-specific antibody S25-2 (C) and the 2→8-2→4 trisaccharide-specific antibody S25-23 (D). gates 6, 12 and 23 and the previously described compound α-Kdo-(2→8)-α-Kdo-(2→4)-α-Kdo-BSA were used as antigens in enzyme immuno-assay with monoclonal antibodies (mAb) of defined specificity. Thus mAb S25-2 and S25-23 are Chlamydia-specific, recognizing as a minimal epitope the α-(2→8)-linked Kdo disaccharide and the α-Kdo-(2→8)-α-Kdo-(2→4)-α-Kdo trisaccharide, respectively. Antibodies with the specificities of mAb S25-23 and S25-2 are also found in human sera 24 and can be determined by the use of defined neoglycoconjugates as those described herein. Mab A20 recognizes a single terminal Kdo residue which occurs in the LPS of many Gram-negative bacteria. Since all compounds investigated here also contain a terminal Kdo, mAb A20 is used to determine the efficacy of immobilizing the glycoconjugates to EIA plates. As shown in Figure 5A , all neoglycoconjugates were efficiently immobilized to the plates since the binding curves obtained with mAb A20 did not differ significantly. Figure  5B shows the binding curves of mAb S25-38 which were comparable with all antigens used. The antibody bound also to α-Kdo-(2→4)-α-Kdo-BSA (data not shown). Thus, mAb S25-38 binds to the 2→4-and 2→8-linked Kdo disaccharide to a similar extent. The binding of mAb S25-2 to compound 6 ( Fig. 5C , column 2) confirmed that this antibody recognizes the α-Kdo-(2→8)-α-Kdo disaccharide portion of the chlamydia-specific trisaccharide. As expected, S25-2 did not bind to compound 12 (Fig. 5C,  column 3 ). The failure of mAb S25-2 and S25-23 to bind to compound 23 (Fig. 5C,D) indicated that for both antibodies the 8-substituted Kdo without additional substitution is required for binding. However, we cannot exclude that the conformation of the (2→8)-linked moiety of tetrasaccharide 21 differs from that determined on the (2→8)-linked disaccharide and α-Kdo-(2→8)-α-Kdo-(2→4)-α-Kdo trisaccharide. 25 In summary, the data confirm and extend our knowledge on the specificity of chlamydial LPS and the antibodies directed against it. We are presently trying to prepare mAbs against the Chl. psittaci-specific compounds 12 and 23 which would be helpful to differentiate Chl. psittaci from Chl. trachomatis strains in human and veterinary diagnostic applications.
